We have patients that may reduce LDL by 50 to 60% with evo or Alirocumab! Please check the supplement of Taussig https://t.co/MLx59Tmk1J
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia - Long term use of PCSK9 inhibitors is safe and effective https://t.co/WD1GaOXtk3
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia https://t.co/9J1nJ8db9w
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia https://t.co/anGhjSa9F9
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. - PubMed - NCBI https://t.co/rdx3xoMbyH
RT @EstebanDL: Disminuir LDL, con evolocumab Efectos adversos? Infecciones virales leves de vias respiratorias altas Curioso...no? Para seg…
RT @JACCJournals: Evolocumab shows long-term safety and efficacy in plasama LDL-C level reduction over a median 4.1 years in severe familia…
RT @JACCJournals: Evolocumab shows long-term safety and efficacy in plasama LDL-C level reduction over a median 4.1 years in severe familia…
RT @JACCJournals: Evolocumab shows long-term safety and efficacy in plasama LDL-C level reduction over a median 4.1 years in severe familia…
Abordagem à dislipidemia nos EssentialCourses!!
Evolocumab shows long-term safety and efficacy in plasama LDL-C level reduction over a median 4.1 years in severe familial hypercholesterolemia patients. How will this impact your practice? https://t.co/q8CPu8VFID #JACC @rauldsf_santos https://t.co/BOxWN5Z
RT @rauldsf_santos: Long-Term Evolocumab in Patients With Familial Hypercholesterolemia https://t.co/EXDSmvJn6Y Good news for our severe FH…
Disminuir LDL, con evolocumab Efectos adversos? Infecciones virales leves de vias respiratorias altas Curioso...no? Para seguir https://t.co/Ch0UKG6zpx @Drlipid https://t.co/hSwHHtzHuq
RT @krychtiukmd: Interesting long term data on Evolocumab in FH (both hoFH and heFH) in @JACCJournals #Cardiotwitter #CardioEd https://…
RT @krychtiukmd: Interesting long term data on Evolocumab in FH (both hoFH and heFH) in @JACCJournals #Cardiotwitter #CardioEd https://…
RT @rauldsf_santos: Long-Term Evolocumab in Patients With Familial Hypercholesterolemia https://t.co/EXDSmvJn6Y Good news for our severe FH…
Congrats! Long- term follow up use of evolucumab!
RT @rauldsf_santos: best of all, may reduce ASCVD events, our rates were roughly half the ones of historical controls for HE and Ho FH !
RT @krychtiukmd: Interesting long term data on Evolocumab in FH (both hoFH and heFH) in @JACCJournals #Cardiotwitter #CardioEd https://…
RT @krychtiukmd: Interesting long term data on Evolocumab in FH (both hoFH and heFH) in @JACCJournals #Cardiotwitter #CardioEd https://…
RT @krychtiukmd: Interesting long term data on Evolocumab in FH (both hoFH and heFH) in @JACCJournals #Cardiotwitter #CardioEd https://…
RT @krychtiukmd: Interesting long term data on Evolocumab in FH (both hoFH and heFH) in @JACCJournals #Cardiotwitter #CardioEd https://…
RT @krychtiukmd: Interesting long term data on Evolocumab in FH (both hoFH and heFH) in @JACCJournals #Cardiotwitter #CardioEd https://…
Interesting long term data on Evolocumab in FH (both hoFH and heFH) in @JACCJournals #Cardiotwitter #CardioEd https://t.co/JlcFmQ9Y0X https://t.co/x3LsR7wIhd
RT @ValleAlfonso: #Evolocumab was 📌well tolerated 📌effectively reduced plasma LDL-C levels in patients with familial hypercholesterolemia (…
RT @rauldsf_santos: Long-Term Evolocumab in Patients With Familial Hypercholesterolemia https://t.co/EXDSmvJn6Y Good news for our severe FH…
RT @ValleAlfonso: #Evolocumab was 📌well tolerated 📌effectively reduced plasma LDL-C levels in patients with familial hypercholesterolemia (…
RT @rauldsf_santos: Long-Term Evolocumab in Patients With Familial Hypercholesterolemia https://t.co/EXDSmvJn6Y Good news for our severe FH…
RT @rauldsf_santos: Long-Term Evolocumab in Patients With Familial Hypercholesterolemia https://t.co/EXDSmvJn6Y Good news for our severe FH…
best of all, may reduce ASCVD events, our rates were roughly half the ones of historical controls for HE and Ho FH !
RT @rauldsf_santos: Long-Term Evolocumab in Patients With Familial Hypercholesterolemia https://t.co/EXDSmvJn6Y Good news for our severe FH…
RT @ValleAlfonso: #Evolocumab was 📌well tolerated 📌effectively reduced plasma LDL-C levels in patients with familial hypercholesterolemia (…
Very interesting. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia https://t.co/jtvjJ2doJR
RT @rauldsf_santos: Long-Term Evolocumab in Patients With Familial Hypercholesterolemia https://t.co/EXDSmvJn6Y Good news for our severe FH…
RT @rauldsf_santos: Now the challenge is access !!!! Let's do our best to fight for patients @atherosociety @TheFHFoundation @AHFbrasil @HF…
RT @rauldsf_santos: Long-Term Evolocumab in Patients With Familial Hypercholesterolemia https://t.co/EXDSmvJn6Y Good news for our severe FH…
RT @ValleAlfonso: #Evolocumab was 📌well tolerated 📌effectively reduced plasma LDL-C levels in patients with familial hypercholesterolemia (…
RT @rauldsf_santos: Long-Term Evolocumab in Patients With Familial Hypercholesterolemia https://t.co/EXDSmvJn6Y Good news for our severe FH…
RT @rauldsf_santos: Long-Term Evolocumab in Patients With Familial Hypercholesterolemia https://t.co/EXDSmvJn6Y Good news for our severe FH…
RT @rauldsf_santos: Now the challenge is access !!!! Let's do our best to fight for patients @atherosociety @TheFHFoundation @AHFbrasil @HF…
RT @rauldsf_santos: Long-Term Evolocumab in Patients With Familial Hypercholesterolemia https://t.co/EXDSmvJn6Y Good news for our severe FH…
Now the challenge is access !!!! Let's do our best to fight for patients @atherosociety @TheFHFoundation @AHFbrasil @HFIberoamerica @fhscglobal @heartukcharity @fhpatienteurope @FHFamiliar #KNOWFH
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia https://t.co/EXDSmvJn6Y Good news for our severe FH patients: Evolocumab has sustained effects and is safe in the long term ! #KNOWFH
RT @ValleAlfonso: #Evolocumab was 📌well tolerated 📌effectively reduced plasma LDL-C levels in patients with familial hypercholesterolemia (…
RT @ValleAlfonso: #Evolocumab was 📌well tolerated 📌effectively reduced plasma LDL-C levels in patients with familial hypercholesterolemia (…
#Evolocumab was 📌well tolerated 📌effectively reduced plasma LDL-C levels in patients with familial hypercholesterolemia (homozygous FH & severe heterozygous FH) over a median of 4.1 years. 📂https://t.co/4EB3wMbWzO @JACCJournals @secardiologia @sea_es h